Navigation Links
Hard to Treat Diseases, Inc. (HTDS) Finalizes Agreement with Yunnan Walvax Biotech
Date:6/15/2009

BEIJING, China, June 15 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK) http://www.htdsmedical.com is pleased to announce that its Mellow Hope Bio Chem China division has signed an agreement with Yunnan Walvax Biotech Co., Ltd on the issue of Haemophilus influenza type "B" conjugate vaccine.

Under the terms of the agreement Mellow Hope will be fully authorized to do the International marketing of Haemophilus influenza type "B" conjugate vaccine in the global market.

HTDS intends to begin the registration process in Chile, India, Indonesia, Egypt, and Russia, commencing in June 2009 with the brand name "MEVAC-Hib".

Yunnan Walvax Biotech Co., Ltd is the second biggest manufacturer of Haemophilus influenza type b conjugate vaccine in China.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events. Note this CTV web link is an unauthorized link, provided for the convenience of the reader.

CONTACT: corporate@htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nicotine Receptors Could Be Lung Cancer Treatment Target
2. Finding Raises Hope for Treating ALS
3. Decision tool for prostate cancer patients helps men customize treatment in anxious time
4. Hebrew University research leads to advanced trials of new cancer treatment
5. Forterus Inc. Treatment Centers Serving Middle-Class; Rapid Growth Detailed in Paul Howarth Interview
6. Desert Oasis Recovery, an Albuquerque, New Mexico Based Drug and Alcohol Rehab Treatment Center Announces Their New Day Treatment Addiction Treatment Program
7. Desert Oasis Recovery, an Albuquerque, New Mexico Based Drug and Alcohol Addiction Treatment Center Announces a New Prescription Drug Addiction Treatment Program
8. Partners Support Helps Men Adhere to Apnea Treatment
9. AUDIO from Medialink and Amgen: Experts Agree Infection in Cancer Patients Impacts Treatment Success
10. New Treatment Option at The Sarah Cannon Cancer Center Provides Hope for Inoperable Tumors
11. Early treatment of systemic onset JIA with anakinra restores the IL-18 response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Tucson, AZ (PRWEB) , ... February 10, 2016 , ... ... prompted the Aging Life Care Association™ (ALCA) to conduct a survey that takes a ... aging experts released today illustrates the prevalence and causes of TBI among the aging ...
(Date:2/10/2016)... ... 10, 2016 , ... United Benefit Advisors (UBA), the nation’s ... to its growing list of Partner Firms. S.S. Nesbitt is headquartered in ... Huntsville and in between. , Harnessing the experience and insights of the agency’s ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... AxoGen, Inc. ... will report results for the fourth quarter and full year ended December 31, 2015 ... a conference call and webcast for the investment community following the release at 4:30 ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The Association for ... speaker Jan Fox will serve as keynote speaker at the organization’s 2016 Spring ... tools to more effectively communicate with their own organizational staff and leadership. ...
(Date:2/10/2016)... AZ (PRWEB) , ... February 10, 2016 , ... For ... in new book , Pioneering book "Better with Age: The Ultimate Guide to Brain ... neuroplasticity can improve memory. The book’s publication date is March 16, 2016. ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... BASEL, Switzerland and SAN DIEGO ... Houston , Inc., a global leader in viral gene ... gene therapy treatments for congestive heart failure and other ... to develop a scalable manufacturing process and produce cGMP-grade ... clinical trials. --> ...
(Date:2/10/2016)... NEW YORK , Feb. 10, 2016 ... clinical-stage biopharmaceutical company, announced today that it has filed ... Myeloid Leukemia and other cancers. --> ... of treating cancer by administration of Ceplene (histamine dihydrochloride) ... also provides methods of predicting the efficacy of Ceplene ...
(Date:2/10/2016)... , Feb. 10, 2016  Oxis International Inc. ... drug, OXS-1550, was described as a "clinical trial triumph" ... drug went into complete cancer remission. ... of Minnesota Masonic Cancer Center. --> ... of Minnesota Masonic Cancer Center. --> ...
Breaking Medicine Technology: